M

Merck

Makes medicines, vaccines and animal treatments

Business Analyst - MLR Review Capability, Veeva PromoMats

Full-TimeUpdated on 10/23/2026Deadline 11/5/26
No salary listed
Senior
Bachelor's
Hyderabad, Telangana, India
HybridHybrid work arrangement.
IT OperationsEnterprise Applications

About the job

Requirements
  • A bachelor's degree in computer science, information technology, engineering, or a related discipline is required.
  • Current Veeva Vault Administrator certification is required.
  • At least 7 years of experience as a Business Analyst, Systems Analyst, Product Analyst, or in a similar role is required.
  • At least 3 years of hands-on experience with Veeva Vault, including strong practical knowledge of PromoMats configuration and administration, is required.
  • Strong understanding of pharmaceutical promotional content and Medical, Legal, and Regulatory (MLR) review processes is required.
  • Experience in Agile/Scrum environments with cross-functional global teams is required, along with proficiency in JIRA, Confluence, and SharePoint.
  • Ability to translate stakeholder needs into clear functional requirements and user stories, and to constructively challenge requirements with pragmatic alternatives, is required.
  • Experience facilitating workshops and review sessions and supporting User Acceptance Testing (UAT) and solution validation is required.
  • Ability to work effectively across a geographically distributed India–Europe–US team is required.
  • Analytical rigor and systems thinking across configuration, process, and integrations are expected.
  • Ownership and attention to compliance and quality are expected.
  • Clear, structured communication and documentation are expected.
  • Collaboration and stakeholder influence across global teams are expected.
  • Required skills listed include data engineering, data visualization, design applications, software configurations, software development, software development life cycle (SDLC), solution architecture, system designs, system integration, and testing.
Responsibilities
  • Analyze and support Veeva Vault PromoMats configuration, including document types, fields, lifecycles, workflows, states, roles, permissions, security profiles, sharing settings, objects, picklists, notifications, renditions, and document relationships.
  • Assess enhancement requests and translate business needs into functional and technical requirements, solution options, configuration specifications, user stories, and acceptance criteria.
  • Perform impact analysis across configuration, metadata, security, workflows, integrations, reporting, and downstream processes before changes are approved.
  • Review the existing Vault setup and identify opportunities for clean-up, rationalization, reuse, and standardization.
  • Mature, prioritize, and maintain the product backlog with the Product Owner/Product Manager based on business value, compliance needs, technical dependencies, and platform strategy.
  • Write user stories covering business intent, existing configuration, proposed behavior, technical considerations, and expected outcomes.
  • Ensure stories meet Definition of Ready with clear acceptance criteria, process flows, data/metadata requirements, security considerations, dependencies, and validation approach.
  • Facilitate refinement, solution design, sprint planning, release readiness, and post-deployment reviews with the global cross-functional team.
  • Apply understanding of promotional content management and MLR review to ensure system changes support compliant and efficient ways of working.
  • Partner with business, architecture, and technical teams on integrations with enterprise digital asset management (DAM), MedComms, content ecosystems, identity/access services, and other connected platforms.
  • Document current- and future-state processes, data flows, integration touchpoints, decision rules, and exception scenarios.
  • Develop and review test scenarios, test cases, and traceability to confirm configured solutions meet approved requirements.
  • Coordinate system, regression, and User Acceptance Testing (UAT), deployment validation, and hypercare.
  • Ensure acceptance criteria address quality, compliance, and MLR risk considerations.
  • Maintain current documentation in JIRA, Confluence, and SharePoint, including requirements, configuration decisions, process maps, test evidence, and release artifacts.
  • Support end-to-end traceability across requirements, design decisions, configuration, testing, approvals, and deployment.
  • Identify opportunities to improve efficiency, scalability, and user experience in MLR review solutions and processes.
  • Own requirements, impact analysis, and configuration recommendations for PromoMats enhancements from intake through design, build, testing, deployment, and production support.
  • Act as the go-to expert on the current Vault setup, driving configuration clean-up, rationalization, reuse, and standardization across markets and business processes.
  • Partner with the Product Owner/Product Manager on backlog maturity, prioritization, and release planning across configuration, integration, validation, and business readiness.
  • Collaborate with architecture and integration teams on PromoMats touchpoints with enterprise DAM, MedComms, content platforms, and identity/access services.
  • Contribute to adjacent MLR priorities as the capability evolves, including automation and AI-assisted review opportunities, in partnership with the wider DCCE team.
Desired Qualifications
  • Experience with PromoMats integrations, such as digital asset management (DAM), MedComms, and identity/access services.
  • Exposure to automation or AI-enabled capabilities in content review.
  • Familiarity with pharmaceutical regulations, computer system validation (CSV), and audit expectations.

About the company

M

Merck

View
Website

Merck develops prescription medicines, vaccines and veterinary treatments for patients, health systems and animal owners worldwide. Its vaccine portfolio includes Gardasil 9, which helps prevent cancers and other diseases caused by several types of human papillomavirus. The company takes potential treatments through laboratory research and clinical trials, then manufactures and sells approved products to drug distributors, hospitals, physicians and governments. Its animal health division sells medicines and vaccines to veterinarians, farmers and pet owners, while selected drug partnerships also earn shared profits or royalties. Founded in 1891, Merck is headquartered in Rahway, New Jersey.

Company Size

10,001+

Company Stage

IPO

Headquarters

Rahway, New Jersey

Founded

1891

Get referred to Merck

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • U.S. employees build retirement benefits: Merck pairs a defined benefit pension with a matching 401(k).
  • Scientists work within a large research network: Merck reports approximately 24,700 employees in R&D.
  • Animal health adds growth: August 2026 results report Q2 sales of $1.8 billion, up 8% year over year.

What critics are saying

  • Job security faces cuts: Merck's active restructuring program eliminates roles and shrinks its global real estate footprint.
  • Keytruda protection narrows: its main U.S. patent expires in 2028, with additional patents expiring in 2029.
  • Revenue is concentrated: August 2026 results show Keytruda products generated $8.4 billion of Merck's $16.6 billion Q2 sales.

What makes Merck unique

  • Merck extends into farm technology: SenseHub continuously monitors livestock for behavioral and physiological changes.
  • Merck publishes open medical knowledge: its Manuals give clinicians and patients free online references.
  • Merck's donation commitment is open-ended: Mectizan supplies for river blindness continue for as long as needed.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Hybrid Work Options

Growth & Insights and Company News

6 month growth

-19%

1 year growth

-20%

2 year growth

-20%
Yahoo Finance
Oct 28th, 2026
Merck's oncology wins lift outlook, but 110x P/E clouds its $141.82 share price

Merck (MRK) is drawing investor attention after oncology trials showed meaningful survival benefits for KEYTRUDA, sacituzumab tirumotecan, and a melanoma vaccine developed with Moderna. The shares closed at $141.82, down 4.37% over seven days and 4.68% over 30 days. They are still up 33.23% this year and 67.74% over one year in total shareholder return. A popular narrative puts fair value at $159.76, making the stock 11% undervalued. Merck plans more than 20 new growth drivers, with management pointing to over $70 billion in mid-2030s revenue potential to offset the KEYTRUDA loss of exclusivity. Valuation remains contested. Merck trades at 110.3 times earnings, against a fair ratio of 50.2, a US pharmaceuticals average of 15.7, and peers at 33.9. Its profit margin is 4.8%.

Yahoo Finance
Oct 26th, 2026
ESMO 2026: Moderna vaccine debate, Roche's $3.6B KRAS bet and Amgen's lung cancer data

Three cancer drug trials drew attention at the European Society for Medical Oncology (ESMO) meeting, with investors and analysts weighing the results. Moderna and Merck's vaccine intismeran autogene cut the relative risk of melanoma recurrence or death by 42% in a Phase 3 trial. Moderna's shares have still fallen by double digits since the results leaked early, as investors question its valuation and the vaccine's manufacturing and commercial potential. Roche's divarasib reduced the risk of death or disease progression by 42% in KRAS G12C lung cancer, beating Krazati and Lumakras. Patients lived a median of about 18 months, versus a year. Roche raised its peak sales forecast from 3.6 billion Swiss francs to 3 billion. Amgen's Imdelltra, combined with Imfinzi, cut the risk of death by 58% in small cell lung cancer. Median survival was 21.1 months, against 12.7 months for Imfinzi alone.

Becker's Hospital Review
Oct 22nd, 2026
Vaccine reduces risk of melanoma recurrence, death by 42%: What to know.

Vaccine reduces risk of melanoma recurrence, death by 42%: What to know. By: Elizabeth Gregerson Receiving a personalized mRNA-based cancer vaccine alongside immunotherapy lowered the risk of recurrence or death by 42% versus immunotherapy alone in a phase 3 clinical trial of patients with surgically resected stage 2B to 4 melanoma. The vaccine, called intismeran autogene and jointly developed by Merck and Moderna, was tested in combination with Merck's immunotherapy Keytruda after surgery as part of the phase 3 INTerpath-001 trial, according to an Oct. 22 news release from the companies. The trial enrolled 1,137 patients, about two-thirds of whom were randomly assigned to receive the vaccine. The vaccine is given in nine doses and is personalized to include up to 34 neoantigens, or proteins specific to each patient's tumor, according to The New York Times. The trial results were leaked online Oct. 22, The Wall Street Journal reported, two days before Merck and Moderna were expected to present the data at the European Society for Medical Oncology conference in Madrid. The leak prompted Merck, Moderna and ESMO to release the full data early. Here are six notes on the trial results: * In addition to lowering the risk of recurrence or death by 42%, intismeran plus Keytruda lowered the risk of distant metastasis or death by 38% compared with Keytruda alone. * Outcomes in the vaccine group were similar to those for Keytruda alone during the first six months while patients completed the vaccine regimen. After six months, a sensitivity analysis showed a 58% lower risk of recurrence or death and a 50% lower risk of distant metastasis or death versus Keytruda alone. * Results were generally consistent across patient subgroups, and no new safety signals emerged. * Robert Vonderheide, MD, president-elect of the American Association for Cancer Research, told the Times the results are on par with "our biggest breakthroughs." However, neither this trial nor an earlier phase 2 trial has yet shown whether the vaccine improves overall survival, the Times reported. Overall survival is considered the gold standard for determining whether a cancer treatment works and can be a requirement for regulatory approval. * Merck plans to apply for regulatory approval as quickly as possible, Marjorie Green, MD, head of oncology clinical development, told the Times. * Personalized cancer vaccines have also shown promise in small studies in pancreatic, kidney and brain cancers, but not all trials have succeeded. BioNTech ended a phase 2 colorectal cancer trial of its personalized vaccine in August after a recommendation from an independent data safety monitoring board. Read more about the cancer vaccine landscape here. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker's is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit We think you might like

Yahoo Finance
Oct 22nd, 2026
Moderna sinks 18% after leak of melanoma vaccine data showing 42% lower recurrence risk

Moderna shares fell 18% after detailed Phase 3 results for its personalised melanoma vaccine, developed with Merck, appeared online two days before their scheduled presentation. The data surfaced on medical news site Oncology Central and was taken down shortly afterwards. Trading in Moderna was halted for volatility. The leaked data still looks positive. Adding the vaccine, intismeran autogene, to Merck's Keytruda cut the risk of recurrence or death by 42% versus Keytruda alone. After two years, 82.2% of patients on the combination were alive and cancer-free, against 70% on Keytruda alone. The trial enrolled 1,137 patients. The stock had risen more than eightfold this year, and traded at about 52x forward sales before the drop. The 42% figure also trails the 49% from the smaller Phase 2b trial. Full results are due at the ESMO Congress on Saturday.

Yahoo Finance
Oct 22nd, 2026
Pfizer's 5.7% yield signals risk: dividends took 108% of free cash flow vs Merck's 66%

Merck's dividend looks safer than Pfizer's, despite Pfizer's higher yield, according to a 24/7 Wall St. comparison. Pfizer yields about 5.7% against Merck's 2.2%. In 2025, Pfizer's dividends used 108% of free cash flow, while Merck's used 66%. In the first half of 2026, Merck's free cash flow covered 174% of its payout; Pfizer's covered about 51%. Merck has raised its quarterly dividend 39% since 2020, to $0.85. Pfizer's rose 13% and has been flat at $0.43 since January 2025. Pfizer is cheaper, at about 10 times 2026 earnings against Merck's 17. Pfizer targets a return to growth from 2029, while Merck's newer drugs are already selling.